Skip to main content

Table 1 Rates of recurrent VTE and bleeding reported in clinical studies of novel oral anticoagulants

From: Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management

Study

Patients, N

Treatment duration

Rate of VTE recurrence

Rate of bleeding

Major bleeding

All bleeding

Major/CRNM bleeding

Schulman 2009 RE-COVER [21]

2564

6 months

Dabigatran 2.4% LMWH + VKA 2.1% Difference 0.4% (95% CI −0.8%, 1.5%); p < 0.001, non-inferior HR 1.10 (95% CI 0.65, 1.84)

aDabigatran 1.6% LMWH + VKA 1.9% HR 0.82 (95% CI 0.45, 1.48)

Dabigatran 16.1%LMWH + VKA 21.9% HR 0.71 (95% CI 0.59, 0.85)

bDabigatran 5.6% LMWH + VKA 8.8% HR 0.63 (95% CI 0.47, 0.84); p = 0.002

Schulman 2011 RE-COVER II [22]

2568

6 months

Dabigatran 2.4% LMWH + VKA 2.2% Difference 0.2% (95% CI −1.0%, 1.5%); p < 0.0001, non-inferior HR 1.08 (95% CI 0.64, 1.80)

aDabigatran 1.2% LMWH + VKA 1.7% HR 0.69 (95% CI 0.36, 1.32)

Dabigatran 15.6% LMWH + VKA 22.1% HR 0.67 (95% CI 0.56, 0.81)

 

EINSTEIN Investigators 2010 EINSTEIN-DVT [18]

3451

3, 6 or 12 months

Rivaroxaban 2.1% LMWH + VKA 3.0% p < 0.001, non-inferior HR 0.68 (95% CI 0.44, 1.04)

cRivaroxaban 0.8% LMWH + VKA 1.2% HR 0.65 (95% CI 0.33, 1.30); p = 0.21

 

dRivaroxaban 8.1% LMWH + VKA 8.1% HR 0.97 (95% CI 0.76, 1.22); p = 0.77

EINSTEIN-PE Investigators 2012 EINSTEIN-PE [19]

4832

3, 6 or 12 months

Rivaroxaban 2.1% LMWH + VKA 1.8% p = 0.003, non-inferior HR 1.12 (95% CI 0.75, 1.68)

cRivaroxaban 1.1% LMWH + VKA 2.2% HR 0.49 (95% CI 0.31, 0.79); p = 0.003

 

dRivaroxaban 10.3% LMWH + VKA 11.4% HR 0.90 (95% CI 0.76, 1.07); p = 0.23

  1. CRNM, clinically relevant non-major; HR, hazard ratio; LMWH, low molecular weight heparin; VKA, vitamin K antagonist.
  2. a: Bleeding defined as major if clinically overt and if it was associated with a fall in the haemoglobin level of at least 20 g/L, resulted in the need for transfusion of 2 or more units of red cells, involved a critical site or was fatal.
  3. b: Clinically relevant non-major bleeding was defined as bleeding not meeting the criteria for major bleeding but associated with spontaneous skin haematoma of at least 25 cm2, spontaneous nose bleed of more than 5 minutes’ duration, macroscopic haematuria (spontaneous or, if associated with intervention, lasting more than 24 hours), spontaneous rectal bleeding (more than spotting on toilet paper), gingival bleeding for more than 5 minutes, bleeding leading to hospitalisation and/or requiring surgical treatment, bleeding leading to a transfusion of less than 2 units of whole blood or red cells, or any other bleeding considered clinically relevant by the investigator.
  4. c: Bleeding was defined as major if it was clinically overt and associated with a fall in the haemoglobin level of 20 g/L or more, or if it led to transfusion of two or more units of red cells, or if it was retroperitoneal, intracranial, occurred in a critical site or contributed to death.
  5. d: Clinically relevant non-major bleeding was defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, interruption or discontinuation of study treatment, or associated with any other discomfort such as pain or impairment of activities of daily life.
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us